MRI Evaluation of the Breast Areolar Margin and Paryenchyma (Breast MRI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01300585|
Recruitment Status : Terminated (Lack of patient population)
First Posted : February 21, 2011
Last Update Posted : May 5, 2014
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Other: MRI||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||68 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||MRI Evaluation to Assess the Relationship Between the Areolar Margin and Underlying Breast Paryenchyma Attachments to the Dermis|
|Study Start Date :||February 2011|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||May 2014|
All patients on study will undergo an MRI of the breast(s).
Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
- Patterns of Breast Gland Attachment [ Time Frame: 6 months ]Identify the various patterns of breast gland attachment to the overlying skin.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300585
|United States, Georgia|
|Atlanta, Georgia, United States, 30309|
|Principal Investigator:||Heather Richardson, MD||Piedmont Hospital|